---
title: "Sinopep-Allsino Biopharmaceutical's Two Drugs Get Chinese Drug Regulator's Approval; Shares Rose 3%"
date: "2025-02-10 13:20:05"
summary: "The Chinese drug administration approved Jiangsu Sinopep-Allsino Biopharmaceutical's two drugs that treat hypercholesterolemia and homozygous familial hypercholesterolemia, according to a Shanghai Stock Exchange disclosure on Monday. The registration certificates for the ezetimibe and atorvastatin calcium tablets (I) and ezetimibe and atorvastatin calcium tablets (II) are both valid until Jan. 23,..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

The Chinese drug administration approved Jiangsu Sinopep-Allsino Biopharmaceutical's two drugs that treat hypercholesterolemia and homozygous familial hypercholesterolemia, according to a Shanghai Stock Exchange disclosure on Monday.

The registration certificates for the ezetimibe and atorvastatin calcium tablets (I) and ezetimibe and atorvastatin calcium tablets (II) are both valid until Jan. 23,Â 2030, the biopharmaceutical company said.

The company's shares rose less than 3% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465442:0/)
